|
[1]Lada O, Benhamou Y, Cahour A, et al. In vitro susceptibility of lamivudine-resistant hepatits B virus toadefovir and tenofovir[J].Antivir Ther, 2004, 9∶353-363.
|
|
[2]Tenney DJ, Levine SM, Rose RE, et al.Clinical emergence of ente-cavir-resistant hepatitisB virus requires additional substitutions invirus already resistant to Lamivudine[J].Antimicrob Agents Che-mother, 2004, 48∶3498-3507.
|
|
[3]Stuyver LJ, Locamini SA, Lok A, et al.Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase re-gion[J].Hepatology, 2001, 33∶751-757.
|
|
[4]Nakanishi H, Kurosaki M, Asahina Y, et al. Polymerase domain Bmutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B[J].Intervirology, 2005, 48∶381-388.
|
|
[5]Chong Y, Stuyver L, Otto MJ, et al.Mechanism of antiviral activi-ties of 30-substituted L-nucleosides against 3T cresistant HBVpolymerase:a molecular modelling approach[J].Antivir Chem Che-mother, 2003, 14∶309-319.
|
|
[6]Delaney IV WE, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replicvation in vitro[J].J Virol, 2003, 77∶11833-11841.
|
|
[7]Lee YS, Chung YH, Ryu SH, et al. Hepatitis B virus with rtL80V/I mutation associates with poor response to adefovir dipivoxil therapy (Abstract 965) [J].Hepatology, 2005, 42∶575A.
|
|
[8]Gish RG. Clinical trial results of new therapies for HBV:implications for treatment guidelines[J].Semin Liver Dis, 2005, 25∶29-39.
|
|
[9]Yuen MF, Lai CL. Adefovir dipivoxil in chronic hepatitis B infection[J].Expert Opin Pharmacother, 2004, 5∶2361-2367.
|
|
[10]Fung SK, Chae HB, Fontana R, et al.HBVgenotype D and switchto adefovir (ADV) monotherapy are associated with increased risk ofADV resistance in chronic hepatitis B (Abstract1001) [J].Hepatol-ogy, 2005, 42∶590A.
|
|
[11] Bartholomeusz A, Locarnini S, Ayres A, et al. Mechanistic basis for hepatitis B virus resistance to acyclic phosphonate analogues, adefovir and tenofovir. (Abstract 1011) [J].Hepatology, 2005, 42∶594 A.
|
|
[12]Lampertico P, Marzano A, Levrero M, et al.A multicenter Italianstudy of rescue adefovir dipivoxil therapy in lamivudine resistant pa-tients:a 2-year analysis of604 patients (Abstract1003) [J].Hepa-tology, 2005, 42∶591A.
|
|
[13]Im GY, Uriel AJ, Carriero D, et al. Comparison of tenofovir versus adefovir based combination therapy in subjects with chronic hepatitis B[J].Hepatology, 2005, 42∶589A.
|
|
[14]Delaney IV WE, Edwards R, Colledge D, et al.Cross-resistancetesting of antihepadnaviral compounds using novel recombinant bacu-loviruses which encode drug-resistant strains of hepatitis B virus[J].Antimicrob Agents Chemother, 2001, 45∶1705-1713.
|
|
[15]Colonno R, Rose R, Levine S, et al.Entecavir two year resistanceupdate:no resistance observed in mucleoside naive patients and lowfrequency resistance emergence in lamivudine refractory patients (Ab-stract 962) [J].Hepatology, 2005, 42∶573A.
|
PDF下载 ( 223 KB)
本文二维码
下载:
